pharmacogenomics-cbs-psp

Precision Pharmacogenomics for CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">pharmacogenomics-cbs-psp</th>
</tr>
<tr>
<td class="label">Enzyme</td>
<td>Chromosome</td>
</tr>
<tr>
<td class="label">CYP2D6</td>
<td>22q13.2</td>
</tr>
<tr>
<td class="label">CYP3A4</td>
<td>7q21.1</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>CBS/PSP Relevance</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>Strong PSP risk factor (H1 haplotype)</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>Risk factor for CBS/PSP with potential synucleinopathy overlap</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>Modulates neurodegeneration and lipid metabolism</td>
</tr>
<tr>
<td class="label">Phenotype</td>
<td>Activity Score</td>
</tr>
<tr>
<td class="label">Poor Metabolizer (PM)</td>
<td>0</td>
</tr>
<tr>
<td class="label">Intermediate Metabolizer (IM)</td>
<td>0.5-1.0</td>
</tr>
<tr>
<td class="label">Normal Metabolizer (NM)</td>
<td>1.5-2.5</td>
</tr>
<tr>
<td class="label">Ultra-rapid Metabolizer (UM)</td>
<td>>2.5</td>
</tr>
<tr>
<td class="label">Allele</td>
<td>Function</td>
</tr>
<tr>
<td class="label">*1 (wild-type)</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">*2</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">*3</td>
<td>Null</td>
</tr>
<tr>
<td class="label">*4</td>
<td>Null</td>
</tr>
<tr>
<td class=

Precision Pharmacogenomics for CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">pharmacogenomics-cbs-psp</th>
</tr>
<tr>
<td class="label">Enzyme</td>
<td>Chromosome</td>
</tr>
<tr>
<td class="label">CYP2D6</td>
<td>22q13.2</td>
</tr>
<tr>
<td class="label">CYP3A4</td>
<td>7q21.1</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>CBS/PSP Relevance</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>Strong PSP risk factor (H1 haplotype)</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>Risk factor for CBS/PSP with potential synucleinopathy overlap</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>Modulates neurodegeneration and lipid metabolism</td>
</tr>
<tr>
<td class="label">Phenotype</td>
<td>Activity Score</td>
</tr>
<tr>
<td class="label">Poor Metabolizer (PM)</td>
<td>0</td>
</tr>
<tr>
<td class="label">Intermediate Metabolizer (IM)</td>
<td>0.5-1.0</td>
</tr>
<tr>
<td class="label">Normal Metabolizer (NM)</td>
<td>1.5-2.5</td>
</tr>
<tr>
<td class="label">Ultra-rapid Metabolizer (UM)</td>
<td>>2.5</td>
</tr>
<tr>
<td class="label">Allele</td>
<td>Function</td>
</tr>
<tr>
<td class="label">*1 (wild-type)</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">*2</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">*3</td>
<td>Null</td>
</tr>
<tr>
<td class="label">*4</td>
<td>Null</td>
</tr>
<tr>
<td class="label">*5</td>
<td>Null</td>
</tr>
<tr>
<td class="label">*10</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">*17</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">*41</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Allele Frequency</td>
</tr>
<tr>
<td class="label">*22</td>
<td>~5-10%</td>
</tr>
<tr>
<td class="label">*1B</td>
<td>~2-5%</td>
</tr>
<tr>
<td class="label">2 to 27</td>
<td>Rare</td>
</tr>
<tr>
<td class="label">Service</td>
<td>Testing Method</td>
</tr>
<tr>
<td class="label">Genomind</td>
<td>Microarray/Sequencing</td>
</tr>
<tr>
<td class="label">OneOme</td>
<td>NGS-based</td>
</tr>
<tr>
<td class="label">Mayo Clinic Pharmacogenomics</td>
<td>Clinical-grade PCR</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>H1 Haplotype</td>
</tr>
<tr>
<td class="label">Population Frequency</td>
<td>~75% (European)</td>
</tr>
<tr>
<td class="label">4R Tau Expression</td>
<td>Upregulated</td>
</tr>
<tr>
<td class="label">CBS/PSP Risk</td>
<td>Strongly increased</td>
</tr>
<tr>
<td class="label">Subhaplotypes</td>
<td>H1a, H1b, H1c, H1P</td>
</tr>
<tr>
<td class="label">Haplotype</td>
<td>Anti-tau Therapy Consideration</td>
</tr>
<tr>
<td class="label">H1/H1</td>
<td>Monitor closely; potential for stronger response</td>
</tr>
<tr>
<td class="label">H1/H2</td>
<td>Intermediate profile</td>
</tr>
<tr>
<td class="label">H2/H2</td>
<td>May require higher doses</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Function</td>
</tr>
<tr>
<td class="label">N370S</td>
<td>Mildly reduced activity</td>
</tr>
<tr>
<td class="label">L444P</td>
<td>Significantly reduced activity</td>
</tr>
<tr>
<td class="label">E326K</td>
<td>Mildly reduced activity</td>
</tr>
<tr>
<td class="label">RecNCI</td>
<td>Severely reduced activity</td>
</tr>
<tr>
<td class="label">Allele</td>
<td>Effect on AD Risk</td>
</tr>
<tr>
<td class="label">ε2</td>
<td>Protective</td>
</tr>
<tr>
<td class="label">ε3 (reference)</td>
<td>Neutral</td>
</tr>
<tr>
<td class="label">ε4</td>
<td>Risk (dose-dependent)</td>
</tr>
<tr>
<td class="label">APOE Genotype</td>
<td>Lipid Therapy Response</td>
</tr>
<tr>
<td class="label">ε2/ε2 or ε2/ε3</td>
<td>Enhanced response</td>
</tr>
<tr>
<td class="label">ε3/ε3</td>
<td>Normal response</td>
</tr>
<tr>
<td class="label">ε3/ε4 or ε4/ε4</td>
<td>Reduced response</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Primary Metabolism</td>
</tr>
<tr>
<td class="label">Levodopa/Carbidopa</td>
<td>COMT, DDC</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>MAO-B, CYP3A4</td>
</tr>
<tr>
<td class="label">Selegiline</td>
<td>CYP2D6, CYP3A4</td>
</tr>
<tr>
<td class="label">Entacapone</td>
<td>COMT</td>
</tr>
<tr>
<td class="label">Amantadine</td>
<td>Renal excretion</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Primary Metabolism</td>
</tr>
<tr>
<td class="label">Sertraline</td>
<td>CYP2C19, CYP2D6</td>
</tr>
<tr>
<td class="label">Escitalopram</td>
<td>CYP2C19, CYP3A4</td>
</tr>
<tr>
<td class="label">Venlafaxine</td>
<td>CYP2D6</td>
</tr>
<tr>
<td class="label">Duloxetine</td>
<td>CYP1A2, CYP2D6</td>
</tr>
<tr>
<td class="label">Bupropion</td>
<td>CYP2B6</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Primary Metabolism</td>
</tr>
<tr>
<td class="label">Donepezil</td>
<td>CYP2D6, CYP3A4</td>
</tr>
<tr>
<td class="label">Rivastigmine</td>
<td>Non-CYP</td>
</tr>
<tr>
<td class="label">Galantamine</td>
<td>CYP2D6, CYP3A4</td>
</tr>
<tr>
<td class="label">Memantine</td>
<td>Renal</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Primary Metabolism</td>
</tr>
<tr>
<td class="label">Quetiapine</td>
<td>CYP3A4</td>
</tr>
<tr>
<td class="label">Lorazepam</td>
<td>Glucuronidation</td>
</tr>
<tr>
<td class="label">Clonazepam</td>
<td>CYP3A4</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>CYP1A2</td>
</tr>
<tr>
<td class="label">Metabolizer Type</td>
<td>CYP2D6 Substrates</td>
</tr>
<tr>
<td class="label">Poor Metabolizer</td>
<td>Reduce 50-75%</td>
</tr>
<tr>
<td class="label">Intermediate</td>
<td>Reduce 25%</td>
</tr>
<tr>
<td class="label">Normal</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Ultra-rapid</td>
<td>Consider increase 50%</td>
</tr>
<tr>
<td class="label">Comorbidity</td>
<td>Gene-Drug Concern</td>
</tr>
<tr>
<td class="label">Cardiovascular disease</td>
<td>Warfarin, clopidogrel</td>
</tr>
<tr>
<td class="label">Diabetes</td>
<td>Metformin</td>
</tr>
<tr>
<td class="label">Renal impairment</td>
<td>Most drugs</td>
</tr>
</table>

Overview

Precision pharmacogenomics offers a transformative approach to treating Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) by tailoring medication selection and dosing to an individual's genetic profile. This page provides a practical guide for clinicians and patients seeking to optimize therapeutic outcomes through genetic-informed prescribing.

The management of CBS and PSP presents unique pharmacological challenges:

• Complex symptom profiles requiring multiple concurrent medications
• Progressive disease necessitating ongoing treatment adjustments
• Age-related changes in drug metabolism
• Overlap with other neurodegenerative conditions (particularly Parkinson's disease)

1. Key Pharmacogenomic Targets in CBS/PSP

1.1 Cytochrome P450 Enzymes

The CYP450 enzyme family is central to drug metabolism in movement disorders. Two enzymes are particularly relevant for CBS/PSP pharmacotherapy:

1.2 Disease-Risk Genes with Therapeutic Implications

2. CYP2D6 and CYP3A4 Variants

2.1 CYP2D6 Polymorphisms

CYP2D6 exhibits extensive genetic polymorphism, resulting in four primary metabolizer phenotypes[@cyp2d6_levodopa]:

Key CYP2D6 Alleles

2.2 CYP3A4 Polymorphisms

CYP3A4 genetic variation is less extensive than CYP2D6 but clinically significant[@cyp3a4_rasagiline]:

2.3 Clinical Impact on CBS/PSP Medications

3. Pharmacogenomic Testing Services

3.1 Commercial Platforms

Three major commercial platforms offer comprehensive pharmacogenomic testing relevant to CBS/PSP:

3.2 Recommended Testing Strategy for CBS/PSP

Tier 1 — Essential Testing:

• CYP2D6 (full allele panel including 1, 2, 3, 4, 5, 6, 10, 17, *41, gene duplication)
• CYP3A4 (*22 allele if available)
• COMT (Val158Met)

• All Tier 1 plus: MAPT haplotype, GBA, APOE

3.3 Interpreting Results

4. MAPT Haplotype and Therapeutic Response

4.1 Haplotype Overview

The MAPT gene exists in two major haplotypes defined by a 900 kb inversion at 17q21.31[@mapt_haplotype_therapy]:

4.2 Clinical Implications for Therapy

MAPT H1 Haplotype Effects:

• Tau-targeted therapies: H1 carriers may show differential response to anti-tau immunotherapies
• Lithium response: Preliminary evidence suggests H1 carriers may respond differently to lithium
• Neuroinflammation: H1 haplotype associated with enhanced neuroinflammatory responses

4.3 Therapeutic Recommendations by Haplotype

5. GBA Variants in CBS/PSP

5.1 Clinical Significance

GBA (glucocerebrosidase) variants are increasingly recognized in CBS/PSP, with important implications[@gba_cbs_psp]:

• 5-10% of PSP cases carry GBA variants
• Often indicates synucleinopathy overlap despite clinical CBS/PSP presentation
• May affect response to ambroxol (GBA modulator under investigation)

5.2 Key GBA Variants

5.3 Pharmacogenomic Implications

GBA Variant Carriers:

• May respond better to ambroxol (under investigation for CBS/PSP)
• Consider synucleinopathy overlap in diagnosis
• Monitor for Parkinson's disease development
• GBA variants affect response to:

6. APOE and Lipid-Based Therapies

6.1 APOE Polymorphisms

APOE has three common alleles affecting lipid metabolism and neurodegeneration[@apoe_lipid_therapy]:

6.2 Impact on CBS/PSP Therapeutics

Lipid-Based Therapies:

• APOE ε4 carriers may show altered response to:
• Omega-3 fatty acid supplements
• Lecithin-based formulations
• Statins (for comorbidities)

• APOE genotype may influence response to anti-tau immunotherapies
• ε4 carriers may show different adverse event profiles

6.3 Dosing Recommendations by APOE

7. Drug-Gene Interaction Tables

7.1 Dopaminergic Medications

7.2 Antidepressants (Commonly Used in CBS/PSP)

7.3 Cognitive Enhancers

7.4 Medications for Psychiatric Symptoms

8. Personalized Dosing Algorithm

8.1 Step-by-Step Dosing Protocol

8.2 Dose Adjustment Quick Reference

9. Special Considerations

9.1 Geriatric Pharmacogenomics

Age-related changes interact with genetic variability:

• Reduced hepatic blood flow: Complements CYP polymorphism effects
• Decreased renal function: Affects drug elimination independent of metabolism
• Polypharmacy: Increases drug-drug interaction potential

9.2 Comorbidity Considerations

9.3 Drug-Drug Interactions

CYP2D6 Inhibitors (avoid or adjust):

• Fluoxetine, Paroxetine
• Quinidine
• Bupropion
• Terbinafine

• Rifampin
• Carbamazepine
• St. John's wort

10. Clinical Implementation

10.1 Practical Workflow

10.2 Resources for Clinicians

• CPIC Guidelines: https://cpicpgx.org
• PharmGKB: https://www.pharmgkb.org
• DPWG (Dutch Pharmacogenetics Working Group): https://www.knmp.nl

11. Related Pages

• [Section 160: Pharmacogenomics and Personalized Medicine in CBS/PSP](/therapeutics/section-160-pharmacogenomics-cbs-psp)
• [Section 216: Advanced Pharmacogenomics for CBS/PSP](/therapeutics/section-216-pharmacogenomics-cbs-psp)
• [CYP2D6 Gene Page](/genes/cyp2d6)
• [CYP3A4 Gene Page](/genes/cyp3a4)
• [MAPT Haplotypes](/genes/mapt-haplotypes)
• [GBA Gene](/genes/gba1)
• [APOE Gene](/genes/apoe)
• [Personalized Treatment Plan for Atypical Parkinsonism](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE
• [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
• [Correcting Gut Microbial Dopamine Imbalance to Support Systemic Dopaminergic Function](/hypothesis/h-d3a64f5c) — <span style="color:#ffd54f;font-weight:600">0.42</span> · Target: DDC
• [Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: APOE
• [Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — <span style="color:#ffd54f;font-weight:600">0.46</span> · Target: APOE
• [APOE4-Selective Lipid Nanoemulsion Therapy](/hypothesis/h-c9c79e3e) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving pharmacogenomics-cbs-psp discovered through SciDEX knowledge graph analysis: